Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : VVUS: VIVUS INC. (NASDAQ) -- Ignore unavailable to you. Want to Upgrade?

To: Mkilloran who wrote (12607)	8/4/1998 7:36:00 PM
From: VLAD	Read Replies (1) \| Respond to of 23519

martin, If I were Vivus I would try to sell at the highest price possible. If I were J&J I would try to buy Vivus for the lowest price possible. I believe that both parties know approximately what Vivus is worth based on effective marketing of their product. If J&J bought the company and effectively and agressively marketed MUSE and then Alibra, I see no reason why they couldn't make $3.00 to $4.00/share once all international markets are opened. So if J&J knows they can do this then $20.00/share does not seem like a Vivus longs dream to me. I guess the question we need to know is, "Does J&J really want to buy Vivus and what kind of profit do they think they can make selling MUSE around the globe?" Maybe we should try to see if we can find a channel to communicate with J&J to find their opinions on this matter.